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A BST R AC T   
 
Aim: To investigate of the effect of intraperitoneal (IP) quercetin and bevacizumab on oxygen-induced 
retinopathy (OIR) model in rats. 
Methods: In the study, 28 newborn rats were used. The OIR model was performed with the 50/10% oxygen 
technique. The study consisted of four groups as a control group (Group I) and OIR groups (Group II, III, and 
IV). IP injection applied to all groups on the postnatal day (PND) 14. Groups I and II were performed 0.9% 
NaCl, Group III was performed IP bevacizumab, and Group IV was performed IP quercetin. All animals were 
sacrificed on PND 18. 
Results: Based on the data obtained from immunohistochemical and histopathological examinations, the 
number of vascular endothelial cell (VEC), vascular endothelial growth factor (VEGF), and tumor necrosis 
factor-α (TNF-α) levels were significantly reduced in Group III and IV compared to Group II. VECs levels 
were 0±0, 32.69±5.77, 2.92±0.63, and 3.64±0.36 in Group I, Group II, Group III, and Group IV, respectively 
(p<0.001). Likewise, VEGF values were 0.15±0.01, 7.57±1.80, 2.45±0.45, and 2.46±0.49, respectively 
(p<0.001). As well as TNF-α values were 0.06±0.01, 8.22±2.24, 2.32±0.32, and 2.29±0.26 in Group I, Group 
II, Group III, and Group IV, respectively (p<0.001). There was no significant difference between Group III 
and Group IV in terms of VEC, VEGF and TNF-α values (range of p values was 0.96-1.00). 
Conclusion: The results of the present study showed that quercetin administration significantly reduced the 
VEC number and suppressed VEGF and TNF-α. Quercetin's anti-inflammatory and anti-angiogenesis effect 
was found to be similar to bevacizumab. 
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Introduction 
Retinopathy of prematurity (ROP) can be 
mimicked in animals using the oxygen-induced 
retinopathy (OIR) model. With this model, the 
vaso-obliterative and neovascularization (NV) 
phases of ROP can be simulated with high 
reproducibility. Therefore, the treatment 
outcome of anti-angiogenic drugs can be 
assessed efficiently [1].  
Diabetic retinopathy (DRP), ROP, and age-
related macular degeneration (AMD) are 
diseases that are seen as common in 
ophthalmology clinics that may result in vision 
loss and are associated with retinal 
angiogenesis and choroidal angiogenesis [2,3]. 
Pro- and anti-angiogenic factors are released in 
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response to hypoxia that occurred in choroid 
and retina. There are many reasons that trigger 
the neovascularization (NV) in the eye, but one 
of the most well-known reasons is vascular 
endothelial growth factor (VEGF) [4]. 
Stimulation of VEGF receptor 2 (VEGFR2) via 
VEGF creates various intracellular signaling in 
vascular endothelial cells (VECs), including 
proliferation, migration, morphogenesis and 
increased permeability [5]. Likewise, another 
potent angiogenic molecule is tumor necrosis 
factor-α (TNF-α) that controls the genes 
encoding adhesion molecules and angiogenic 
mediators [6]. 
As a monoclonal antibody, bevacizumab 
inhibits VEGF, which is an angiogenic 
cytokine. It prevents pathological angiogenesis 
through promoting vascular leakage and growth 
[7].  It has been documented that off-label use 
of bevacizumab is effective in the treatment of 
many intraocular vascular proliferation retinal 
diseases associated with ischaemic retinopathy, 
such as DRP, ROP, and retinal vein occlusion 
(RVO) [8,9]. 
Quercetin (3,3’, 4’,5,7-penthydroxy flavone) 
belongs to the polyphenol family, which is one 
of the most abundant flavonoid in the diet, and 
is present in many fruits and vegetables, 
including onions, apples and grapes [10]. 
Previous in vivo and in vitro studies have 
shown that quercetin decreases oxidative stress, 
retinal neurodegeneration, and NV effectively 
[11,12]. Moreover, VEGF-induced cell 
proliferation, migration and tube formation was 
inhibited by quercetin [13]. Likewise, 
quercetin-treated retinas showed significantly 
lower levels of TNF-α and other pro-
inflammatory cytokines [14]. 
The impact of quercetin on many organs, 
including the eye has been extensively studied. 
However, less is known about the impacts of 
intraperitoneal (IP) administration of quercetin 
on anti-VEGF factors using OIR models. The 
objective of the present study was therefore to 
investigate the effect of quercetin on VEGF, 
TNF-α, and VEC using OIR models and 
comparing the results with those of 
bevacizumab. 
 
Materials and methods 
This study was conducted in compliance with 
the recommendations of the ARVO Statement 
for Animal Use in Ophthalmic and Vision 
Studies. The research was also accepted by the 
Bolu Abant Izzet Baysal University 
Experimental Animal Studies Ethics 
Committee (Date / decision no: 2018/35).  
 
Creating the OIR Model 
In the present study, 28 newborn Sprague 
Dawley rats were used. All animals were kept 
in a controlled room with 22-24 °C temperature 
and 45-60 % relative humidity with 12h light: 
12h dark conditions. The food and water were 
provided ad libitum. In the 50/10 OIR model, 
lactating pups were placed in an oxygen 
regulated environment with their mothers 
within 4 h following birth, where they were 
exposed to 50 % oxygen for 24 h followed by 
10% oxygen for 24 h [15]. This cycle was 
repeated until postnatal day (PND) 14 seven 
times. Daily monitoring of oxygen levels was 
performed and was calibrated as needed. 
Likewise, daily carbon dioxide levels in the 
cage were also monitored and sufficient gas-
flow was maintained through flushing it from 
the system and adding soda lime. Pups were put 
into a room with ambient air for 4 days on PND 
14. 
The experiment was performed with four 
groups with seven animals per group. The 
injections were administered intraperitoneally 
to all animals only once on day 14 of the 
creation of the OIR model. 
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Group I: The healthy group administered 0.01 
ml ip 0.9% NaCl solution (control group). 
Group II: OIR group administered 0.01 ml ip 
0.9 % NaCl solution (Untreated OIR group). 
Group III: OIR group treated with 0.01 ml ip 
bevacizumab (2.5 mg/kg body weight) 
(Altuzan, Roche, Istanbul, Turkey). Group IV: 
OIR group treated with 0.01 ml ip quercetin (20 
mg/kg body weight) (Sigma-Aldrich, St.Louis, 
USA) [16]. It is assumed that the OIR pattern is 
best formed PNDs 18-20. Therefore, on PND 
18, all animals were sacrificed with high dose 
intracardiac anesthesia, and the right eyes were 
enucleated [17]. The tissues were stored for 
further histopathological and 
immunohistochemical analyses.  
 
Haematoxylin and eosin (H&E) staining 
The eyes were set in 10 percent neutral buffered 
formalin in PBS overnight at 4 °C and then 
embedded in paraffin. The serial sections (4 µm 
thick) of the whole eye were performed sagittal 
that was parallel to the optic nerve and stained 
with H&E. The nuclei of retinal VECs on the 
vitreal side of the retinal inner limiting 
membrane (ILM) were counted by an objective 
observer blind to treatment in ten parts for each 
eye at 400x magnification and the mean number 
of nuclei of endothelial cells for each eye was 
determined for each community [18]. 
 
Immunohistochemistry staining 
A biotin-streptavidin HRP detection kit 
(ab93697; Abcam, Cambridge, UK) was used 
to perform immunohistochemistry. Antigen 
retrieval was performed with citrate buffer. 3 % 
H2O2 in methanol was used for blocking 
endogenous peroxidases for 15 min. In order to 
eliminate non-specific binding, a blocking 
serum was used for the pretreatment of the 
sections. Then, the sections were incubated 
overnight with the following antibodies: anti-
TNF alpha polyclonal antibody (1:250 dilution; 
ab183896; Abcam) and anti-VEGF monoclonal 
antibody (1:50 dilution; sc-7269; Santa, Santa 
Cruz, CA, USA) at 4°C. An appropriate non-
immune immunoglobulin G was used as a 
primary antibody replacement to perform 
negative control incubations. Then, 
biotinylated secondary antibodies were used to 
incubate the tissues. The peroxide complex was 
visualized using 3,3-diaminobenzidine. Finally, 
Mayer’s hematoxylin (Invitrogen, California, 
USA) was used to counterstain the tissues, and 
then they were mounted with Entellan (Merck, 
Darmstadt, Germany) on glass slides. The 
images were observed under a light microscope 
(Leica DM 1000, Germany) and photos were 
taken using Leica DMC 2900 (CH-9435 
Heerbrugg, Germany).  
The following scales were used to grade of 
section: no expression (0), mild (1), moderate 
(2), strong (3), and very strong expression (4) 
by two independent observers blind to 
treatment. The percentage of positive cells was 
described as (0), < 5%; (1), 6% to 15%; (2), 
16% to 50%; (3), 51% to 80%; and (4), > 80% 
of positive cells [19]. The mean value of the 
three retinal sections of each rat was 
determined. 
 
Statistical analyses  
In the present study, the data were analyzed 
using SPSS statistical software package, 
version 25.0 (SPSS Inc., Chicago, IL, USA). 
The data were reported as mean ± standard 
deviations (SDs) for each data set. A statistical 
significance was considered if p<0.05. The 
homogeneity and normality of the sample 
distribution of data were determined using 
Levene’s test and Kolmolgorov Smirnov test, 
respectively. The statistical analyses of the data 
was performed with one-way analysis of 
variance test and post hoc Tukey's test.  
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Representative hematoxylin and eosin-stained 
retinas of all groups are presented in Figure 1. 
In the untreated OIR group (Group II), 
abundant longitudinal and transverse aberrant 
microvessels were noted in ILM. The nuclei of 
VECs were counted to quantify NV. 
Bevacizumab (Group III) and Quercetin (Group 
IV) administered groups showed a reduced 
number of VECs breaching ILM as well as 
improvement of vascular tufts and dilated 
vessels. In Group I (control group), there were 
no VEC nuclei detected on the vitreal side of 






























However, the retinal VEC nucleus number was 
significantly higher in Group II compared with 
Group III and Group IV (Figure 1). On the other 
hand, VEC nucleus number were similar 
between Group III and Group IV (p=0.960; 
Figure 1). 
VEGF and TNF-α levels in the control and OIR 
groups were determined through 
immunohistochemistry (Table 1). VEGF-
positive staining was apparent in the retinas of 
OIR rats, especially in the GCL and INL layers 
(Figure 2). The intensity of the VEGF staining 





























                      
Figure 1. Haematoxylin and Eosin staining of neovascularization in retinal tissues. A: Control group (Group 
I). B: Untreated OIR group (Group II). C: OIR group treated with intraperitoneal bevacizumab (Group III). D: 
OIR group treated with intraperitoneal quercetin (Group IV). Quantitative analysis was performed by counting 
the nuclei of retinal vascular endothelial cells (arrows) on the vitreal side of the inner limiting membrane in 10 
sections from each eye. GCL: Ganglion cell layer, ILM: Inner limiting membrane, INL: Inner nuclear layer, 
IPL: Inner plexiform layer, OLM: Outer limiting membrane, ONL: Outer nuclear layer, OPL: Outer plexiform 
layer, PL: Photoreceptor layer, VB: Vitreous body. 
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quantification of VEGF immune-intensity 
demonstrated that VEGF staining was 
significantly decreased in Group III and Group 
IV compared with Group II (p<0.001 per group 
compared). Moreover, quercetin treatment 
reversed the oxygen-induced VEGF elevation 
that was compatible with bevacizumab.  
Semi-quantification of TNF-α immune-
intensity demonstrated that TNF-α staining was 
significantly decreased in Group III and Group 
IV compared with Group II (p<0.001 per group 
compared). Quercetin treatment reversed the 
oxygen-induced TNF-α elevation (Figure 3). 
Retinal VEGF and TNF-α expression were 
significantly increased in Group II compared to 
Group I, III, and IV (Table 1 and Figure 2). On 
the other hand, levels of VECs, VEGF, and 
TNF-α were significantly decreased in Group 
III and Group IV compared to Group II 























Post hoc test results of VECs, VEGF and TNF-
α in Group II were significantly higher 
compared to Group I, III, and IV (p<0.001 per 
group compared). While the nucleus number of 
VECs was similar between Group I and III, 
VEGF and TNF-α levels were found to be 
significantly reduced in Group III (p=0.30, 
p=0.001, and p=0.008, respectively). Likewise, 
the nucleus number of VEC was similar 
between Group I and IV (p=0.14). In addition, 
VEGF and TNF levels were significantly 
reduced in Group IV (p=0.001 and p=0.009, 
respectively). The nucleus number of VEC, as 
well as VEGF and TNF levels, were similar 
between Group III and IV (p=0.96, p=1.000, 
and p=1.000, respectively). 
 
Discussion 
Retinal NVs are the primary reasons for vision 
loss in patients,   including neovascular   AMD,  
Table 1. The results of H&E and immunohistochemical staining in the OIR model. 
Variables Group I Group II Group III Group IV P* 
VEC nuclei 0 32.69 ± 5.77 2.92 ± 0.63 3.64 ± 0,36 <0.001 
TNF-α 0.06 ± 0.01 8.22 ± 2.24 2.32 ± 0.32 2.29 ± 0,26 <0.001 
VEGF 0.15 ± 0.01 7.57 ± 1.80 2.45 ± 0.45 2.46 ± 0,49 <0.001 
Values: mean ±SD. H&E: Hematoxylin & eosin. OIR:  oxygen-induced retinopathy. 
*One-way analysis of variance test 
Group I: 0.01 ml intraperitoneal saline solution (0.9% NaCl) was administered without creating an OIR 
model (control group). 
Group II: 0.01 ml intraperitoneal saline solution was administered following the creation of the OIR model 
(Untreated OIR group).  
Group III: 0.01 ml intraperitoneal bevacizumab (2.5 mg/kg body weight) (Altuzan, Roche, Istanbul, Turkey) 
was administered in the OIR group. 
Group IV: 0.01 ml intraperitoneal quercetin (20 mg/kg body weight) (Sigma-Aldrich, St.Louis, USA) was 
administered in the OIR group. 
TNF-α: Tumor necrosis factor-α, VEC: Vascular endothelial cell, VEGF: Vascular endothelial growth factor.  
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proliferative DRP, RVO, and ROP. The results 
of the present study demonstrated that ip 
administration of quercetin following an OIR 
model histopathologically suppressed the 
retinal NVs and inflammatory cell infiltration 
as well as significantly reduced the number of 
VECs, VEGF, and TNF-α levels compared to 
the non-treated OIR groups. The data obtained 
with quercetin administration were comparable 
to that of the bevacizumab administration. 
Stimulation of VECs in the case of retinal 
hypoxia could increase the mRNA transcript 
abundance of various genes, including growth 





























TNF-α [20]. Chen et. al. suggested that various 
stages of angiogenesis, including proliferation, 
migration, and tube formation of choroidal and 
retinal VECs, were inhibited following 
quercetin administration in vitro [21]. 
Likewise, Li et al. found that VEGF-induced 
choroidal and retinal angiogenesis were 
inhibited by in vitro quercetin administration 
[13]. It was reported that quercetin could inhibit 
blood vessel development and reduce cell 
viability, cell proliferation, and tube formation 
[22]. Similar to the previously published 
studies, our results suggested that quercetin 
significantly reduced VECs in the experimental  
 
                 
Figure 2. VEGF expressions were determined by immunohistochemistry in non-treated OIR, and OIR rats 
treated with quercetin or bevacizumab. A: Control group (Group I). B: Untreated OIR group (Group II). C: 
OIR group treated with intraperitoneal bevacizumab (Group III). D: OIR group treated with intraperitoneal 
quercetin (Group IV). GCL: Ganglion cell layer, ILM: Inner limiting membrane, INL: Inner nuclear layer, 
IPL: Inner plexiform layer, ONL: Outer nuclear layer, OPL: Outer plexiform layer, PL: Photoreceptor layer. 
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OIR model, and suppressed the synthesis of 
VEGF and TNF-α. 
Currently, intravitreal bevacizumab has been 
successfully used for the treatment of DRP, 
ROP, RVO, and AMD. Many studies have 
reported that it has strong anti-VEGF properties 
and similar efficiency compared to the other 
intravitreal agents (such as aflibercept and 
ranibizumab) [7,8]. Significant improvement 
was shown in the zone I ROP following 
treatment with intravitreal bevacizumab as an 
anti-VEGF monotherapy and was comparable 
to the conventional laser therapy [23]. In the 
current study, the administration of quercetin 




























properties compared to the non-treated OTNF-
α is an important mediator of retinal 
neuroinflammation and neurodegeneration. It 
has previously demonstrated that the cytokines 
and chemokines were strongly suppressed by 
bevacizumab in the experimental OIR model 
[24]. Likewise, cytokine levels were 
significantly reduced in quercetin-treated 
retinas compared to the proliferative diabetic 
retinas [25]. To the best of our knowledge, there 
are no previous studies examining the impact of 
quercetin administration on TNF-α levels using 
experimental OIR models. The results of the 
current study were comparable to that of DRP 
models. Similar to the bevacizumab 
                     
Figure 3. TNF-α expressions were determined by immunohistochemistry in non-treated OIR, and OIR rats 
treated with quercetin or bevacizumab. A: Control group (Group I). B: Untreated OIR group (Group II). C: 
OIR group treated with intraperitoneal bevacizumab (Group III). D: OIR group treated with intraperitoneal 
quercetin (Group IV). GCL: Ganglion cell layer, ILM: Inner limiting membrane, INL: Inner nuclear layer, 
IPL: Inner plexiform layer, ONL: Outer nuclear layer, OPL: Outer plexiform layer. 
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administration, quercetin treatment in the OIR 
model significantly suppressed TNF-α 
compared to the non-treated OIR group.  
The single-dose i.p. administration of quercetin 
in the OIR model and examination of only 
VECs, VEGF and TNF-α limited the strength 
of the study. In addition, dose-response 
relationship, pharmacokinetic and functional 
analyses were not evaluated in the current 
study. Therefore, future studies are required to 
determine the optimal dosing protocol, 
especially for intravitreal application. Although 
the short-term effects were quite promising, 
future studies should be performed to confirm 
the long-term effects. Despite all these 
limitations, it was found in the present study 
that quercetin has comparable efficacy to 
bevacizumab, the anti-VEGF agent currently 
used in routine therapy. 
In conclusion, the results of the present study 
demonstrated that quercetin administration as a 
therapeutic agent may ameliorate the severity of 
OIR in a rat model. Moreover, the effects 
obtained by quercetin treatment using the OIR 
model were comparable to the effects obtained 
following bevacizumab administration. 
Therefore, quercetin administration is 
promising for the treatment of diseases causing 
vision loss in patients, including ROP, DRP, 
RVO, and AMD. However, more studies are 
required in the future for a better conclusion.  
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